Feasibility and safety of laparoscopic surgery for metachronous colorectal cancer.
OBJECTIVE
This study assessed the feasibility and safety of laparoscopic surgery for metachronous colorectal cancer in patients who had previously undergone surgery for primary colorectal cancer.


METHODS
Of the 52 patients who underwent curative resection for metachronous colorectal cancer from August 2004 to April 2013, 26 each underwent laparoscopic and open surgery. Their clinical characteristics and surgical and postoperative outcomes were compared.


RESULTS
The percentage of patients who underwent previous open surgery was significantly higher in the open group than in the laparoscopic group (92.3 vs. 65.4 %). The body mass index was higher in the laparoscopic group than in the open group (23.8 vs. 21.1 kg/m(2)), and the amount of blood loss was significantly smaller in the laparoscopic than in the open group (30 vs. 195 ml); however, the mean operative time did not differ significantly. The time to first flatus (1 vs. 3 days) and first stool (2 vs. 3.5 days), as well as the length of postoperative hospital stay (10 vs. 16 days), was significantly shorter in the laparoscopic group than in the open group, although the rates of postoperative complications did not differ (15.4 vs. 23.1 %).


CONCLUSIONS
Laparoscopic surgery for metachronous colorectal cancer shows short-term benefits compared with open surgery and should be considered as a treatment option in these patients.
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Toshiya
T
Nagasaki
Takashi
T
Akiyoshi
Masashi
M
Ueno
Yosuke
Y
Fukunaga
Satoshi
S
Nagayama
Yoshiya
Y
Fujimoto
Tsuyoshi
T
Konishi
Masami
M
Arai
Toshiharu
T
Yamaguchi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000601:surgery*; D005240:Feasibility Studies; D005260:Female; D005813:Genes, Synthetic; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000601:surgery*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012449:Safety; D016896:Treatment Outcome; D055815:Young Adult
D011994:Recombinant Proteins; C085784:TBI protein, recombinant